Text AA

Comments to FDA on Naloxone in Community Settings

SUBMISSION TO FDA’s JOINT ANESTHETIC & ANALGESIC DRUG PRODUCTS & DRUG SAFETY & RISK MANAGEMENT ADVISORY COMMITTEES

The expansion of access to naloxone to laypersons for use outside of hospital settings has become a core strategy at both the federal and state levels in responding to the prescription opioid and heroin overdose epidemic. Layperson access to naloxone was pioneered by the harm reduction community 20 years ago. In early October, Harm Reduction Coalition submitted a statement to a joint meeting of the Food & Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to address the need of appropriate dosing for naloxone in community settings.

Read our submission to the FDA on naloxone dosing in community settings

Designed & Developed by Firefly Partners